–
Статьи в журналах
-
- 2012 Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output
- Bohn Anja B., Norregaard Rikke, Stodkilde Lene, Wang Yan, Bertelsen Lotte B., Fenton Robert A., Matchkov Vladimir V., Bouzinova Elena V., Horsman Michael R., Frokior Jorgen, Stodkilde-Jorgensen Hans
- в журнале American Journal of Physiology - Regulatory Integrative and Comparative Physiology, издательство American Physiological Society (United States), том 303, № 2, с. R186-R198 DOI